LYPLAL1

Across TCGA pan-cancer cohorts, LYPLAL1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LYPLAL1 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LYPLAL1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LYPLAL1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where LYPLAL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.611	0.405	.017	9	view →
HNSC	DFS	Tertile	IV	0.524	0.768	.031	4	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	4	view →
CCRCC	OS	Median	IV	0.451	1.000	.016	3	view →
LSCC	DFS	Median	III,IV	0.447	0.813	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LYPLAL1–PDAC (OS)

Open the PDAC breakdown →